Failure of bromocriptine therapy to control juvenile mammary hypertrophy

Br J Plast Surg. 2001 Dec;54(8):720-3. doi: 10.1054/bjps.2001.3691.

Abstract

Rapid massive breast hypertrophy occasionally occurs at the time of puberty or during pregnancy, with breast size eventually becoming burdensome or incapacitating to the patient. Pregnancy-related breast hypertrophy is often arrested or reversed by reducing serum prolactin levels with bromocriptine therapy. Unfortunately, breast enlargement in our 12-year-old patient with massive juvenile mammary hypertrophy was unaffected by bromocriptine therapy despite a reduction of her prolactin to normal levels. Two reduction mammaplasties followed by subcutaneous mastectomy were required to control breast hypertrophy. Breast-tissue hypersensitivity to prolactin appears to be a characteristic of pregnancy-related gigantomastia. Our pubertal patient with juvenile mammary hypertrophy failed to respond to bromocriptine therapy, so the aetiology of this syndrome may involve breast-tissue hypersensitivity to hormones other than prolactin.

Publication types

  • Case Reports

MeSH terms

  • Breast / pathology*
  • Bromocriptine / therapeutic use*
  • Child
  • Female
  • Hormone Antagonists / therapeutic use*
  • Humans
  • Hyperprolactinemia / complications
  • Hypertrophy / drug therapy
  • Hypertrophy / surgery
  • Mammaplasty / methods
  • Mastectomy, Subcutaneous
  • Prolactin / antagonists & inhibitors*
  • Treatment Failure

Substances

  • Hormone Antagonists
  • Bromocriptine
  • Prolactin